[{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trientine Hydrochloride","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Manchester University NHS FT","sponsor":"National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trientine Hydrochloride","moa":"Copper","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Manchester University NHS FT","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford","highestDevelopmentStatusID":"8","companyTruncated":"Manchester University NHS FT \/ National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford"}]

Find Clinical Drug Pipeline Developments & Deals for Trientine Hydrochloride

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 13, 2023

                          Lead Product(s) : Trientine Hydrochloride

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Manchester University NHS FT

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Manchester University NHS FT

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Trientine Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Phase II

                          Sponsor : National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 12, 2021

                          Lead Product(s) : Trientine Hydrochloride

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Sponsor : National Institute for Health Research, UK | University of Manchester | University of Liverpool | Univar Inc | University of Oxford

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 27, 2015

                          Lead Product(s) : Trientine Hydrochloride

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 10, 2013

                          Lead Product(s) : Trientine Hydrochloride

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Aptiv Solutions

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Yale University

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Yale University

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 17, 2011

                          Lead Product(s) : Trientine Hydrochloride

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Bausch Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank